Holen Sie sich die Stockscreener-App
50.54
0.48%
0.24
Vorhandelsmarkt:
50.54
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Warum fällt TGTX?
Forum
Prognose
Aktiensplit
Schlusskurs vom Vortag:
$50.30
Offen:
$50.41
24-Stunden-Volumen:
1.99M
Relative Volume:
0.92
Marktkapitalisierung:
$7.74B
Einnahmen:
$700.35M
Nettoeinkommen (Verlust:
$461.90M
KGV:
17.61
EPS:
2.8696
Netto-Cashflow:
$-14.19M
1W Leistung:
+16.53%
1M Leistung:
+27.95%
6M Leistung:
+64.14%
1J Leistung:
+41.85%
1-Tages-Spanne:
$49.00
$50.80
1-Wochen-Bereich:
$43.01
$50.80
52-Wochen-Spanne:
$25.28
$50.80
Tg Therapeutics Inc Stock (TGTX) Company Profile
Firmenname
Tg Therapeutics Inc
Sektor
Branche
Telefon
(212) 554-4484
Adresse
2 GANSEVOORT STREET, 9TH FLOOR, NEW YORK, NY
Compare TGTX vs VRTX, REGN, ARGX, ALNY, RVMD
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
TGTX
Tg Therapeutics Inc
|
50.54 | 7.70B | 700.35M | 461.90M | -14.19M | 2.8696 |
VRTX
Vertex Pharmaceuticals Inc
|
453.17 | 114.33B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
614.73 | 64.47B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
878.49 | 54.99B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
281.90 | 38.42B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
156.58 | 34.03B | 742.00K | -1.37B | -1.07B | -7.0731 |
Tg Therapeutics Inc Stock (TGTX) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-10-06 | Fortgesetzt | H.C. Wainwright | Buy |
| 2025-07-10 | Fortgesetzt | Goldman | Neutral |
| 2024-10-29 | Eingeleitet | TD Cowen | Buy |
| 2023-08-02 | Hochstufung | Goldman | Sell → Neutral |
| 2023-06-26 | Fortgesetzt | Jefferies | Buy |
| 2022-05-20 | Eingeleitet | BofA Securities | Underperform |
| 2022-02-23 | Bestätigt | B. Riley Securities | Buy |
| 2021-11-15 | Herabstufung | Goldman | Neutral → Sell |
| 2021-04-20 | Eingeleitet | Goldman | Neutral |
| 2021-04-19 | Bestätigt | H.C. Wainwright | Buy |
| 2020-09-01 | Eingeleitet | JP Morgan | Overweight |
| 2020-08-11 | Bestätigt | H.C. Wainwright | Buy |
| 2020-06-05 | Eingeleitet | Evercore ISI | Outperform |
| 2020-01-17 | Bestätigt | H.C. Wainwright | Buy |
| 2019-11-27 | Fortgesetzt | B. Riley FBR | Buy |
| 2019-02-06 | Fortgesetzt | Jefferies | Buy |
| 2018-09-25 | Herabstufung | Raymond James | Strong Buy → Outperform |
| 2018-03-09 | Bestätigt | B. Riley FBR, Inc. | Buy |
| 2017-12-01 | Fortgesetzt | B. Riley FBR, Inc. | Buy |
| 2017-11-14 | Fortgesetzt | H.C. Wainwright | Buy |
| 2017-04-25 | Eingeleitet | Jefferies | Buy |
| 2017-03-06 | Bestätigt | FBR & Co. | Outperform |
| 2016-10-06 | Fortgesetzt | Brean Capital | Buy |
| 2016-05-27 | Eingeleitet | SunTrust | Buy |
| 2015-12-01 | Eingeleitet | FBR Capital | Outperform |
| 2015-09-09 | Eingeleitet | Raymond James | Strong Buy |
| 2015-08-12 | Fortgesetzt | H.C. Wainwright | Buy |
| 2015-06-19 | Bestätigt | Brean Capital | Buy |
| 2014-12-11 | Bestätigt | ROTH Capital | Buy |
| 2014-12-10 | Bestätigt | ROTH Capital | Buy |
Alle ansehen
Tg Therapeutics Inc Aktie (TGTX) Neueste Nachrichten
TG Therapeutics Stock On Fire: Up 25% With 6-Day Winning Streak - Trefis
Director Sagar Lonial receives 8,325 stock tracking units at TG Therapeutics (TGTX) - Stock Titan
TG Therapeutics (TGTX) director awarded 8,325 Stock Tracking Units in Form 4 filing - Stock Titan
[Form 4] TG THERAPEUTICS, INC. Insider Trading Activity - Stock Titan
TG Therapeutics (NASDAQ: TGTX) director awarded 8,325 stock tracking units - Stock Titan
Director at TG Therapeutics (TGTX) granted 8,325 stock tracking units - Stock Titan
Top 3 Health Care Stocks That May Collapse This Quarter - Benzinga
TG Therapeutics, Inc. (TGTX) Stock Analysis: A Biotech Powerhouse with Promising Revenue Growth and Analyst Confidence - DirectorsTalk Interviews
TG Thera posts early-stage data for Briumvi in myasthenia gravis; launches mid-stage trial - MSN
TG Therapeutics (TGTX) soars 7.5%: Is further upside left in the stock? - MSN
TGTX stock up on positive phase I data for subcutaneous Briumvi - MSN
Why is TG Therapeutics (TGTX) down 5.7% since last earnings report? - MSN
5-Day Rally Sends TG Therapeutics Stock Up 23% - Trefis
TG Therapeutics Stock Rockets 23% With 5-Day Winning Streak - Trefis
TG Therapeutics Shareholders Reject Executive Compensation at Meeting - TipRanks
Shareholders at TG Therapeutics (NASDAQ: TGTX) reject 2026 executive pay - Stock Titan
TGTX rises on positive phase I data for subcutaneous Briumvi in MG - MSN
TG THERAPEUTICS INC (TGTX) Stock Chart - ChartMill
TGTX Stock Quote Price and Forecast - CNN
TG Therapeutics (TGTX) Is Up 18.5% After Positive Subcutaneous BRIUMVI Phase 1 Data Is Released - Sahm
TGTX: Directors and auditors were approved, but executive compensation was not - TradingView
TG Therapeutics posts late-stage trial win for Briumvi single infusion regimen - MSN
TG Therapeutics Inc Annual Shareholders Meeting Transcript - GuruFocus
TG Therapeutics (TGTX) Soars 7.5%: Is Further Upside Left in the Stock? - Yahoo Finance
TG Therapeutics stock hits 52-week high at 44.7 USD By Investing.com - Investing.com Australia
TGTX Climbs on Upbeat Subcutaneous BRIUMVI Data and Expanded Development Plans - Moomoo
TGTX climbs on upbeat subcutaneous BRIUMVI data and expanded development plans - Quiver Quantitative
TGTX Stock Surges As Briumvi Pipeline Momentum Accelerates - StocksToTrade
TGTX Stock Jumps As Briumvi Pipeline Momentum Accelerates - timothysykes.com
TGTX Stock Surges As Briumvi Data Fuel Growth Story - StocksToTrade
Why TG Therapeutics (TGTX) Is Up 18.4% After Advancing At‑Home Subcutaneous BRIUMVI In MS Treatment - Yahoo Finance
TG Therapeutics Stock Is Surging Today: What's Driving The Action? - Benzinga
TG Therapeutics stock hits 52-week high at 44.7 USD - Investing.com
TGTX Rises on Positive Phase I Data for Subcutaneous Briumvi in MG - Yahoo Finance
TG Therapeutics rises on early-stage trial data for Briumvi injectable - MSN
TG Therapeutics Stock Tumbles 16% After Disappointing Q2, But Company Reaffirms Confidence In Multiple Sclerosis Drug - MSN
TGTX stock jumps 5% on positive early data for at-home BRIUMVI in muscle disease - MSN
TGTX Stock Jumps 5% On Positive Early Data For At-Home BRIUMVI In Muscle Disease - Stocktwits
TG Therapeutics Inc at Goldman Sachs Healthcare Conference Transcript - GuruFocus
TG Therapeutics initiates phase 2 trial of BRIUMVI for MG By Investing.com - Investing.com Australia
TG Therapeutics rallies on positive subcutaneous BRIUMVI data for MG - grafa.com
Why Is TG Therapeutics Stock Gaining Tuesday? - Benzinga
TG Therapeutics (TGTX) Launches Mid-Stage Trial for Briumvi in M - GuruFocus
TG Therapeutics (TGTX) Unveils Positive Phase 1 Data for Briumvi in Myasthenia Gravis - GuruFocus
TG Therapeutics Begins Phase 2 Myasthenia Gravis Trial - Moomoo
TG Therapeutics initiates phase 2 trial of BRIUMVI for MG - Investing.com UK
TG Therapeutics Announces Positive Topline Phase 1 Data for Subcutaneous BRIUMVI in Patients with Myasthenia Gravis and Initiation of Potential Registration Directed Randomized Phase 2 Trial - The Manila Times
82% of myasthenia gravis patients improved in early BRIUMVI shot test - Stock Titan
A Look At TG Therapeutics (TGTX) Valuation After Recent Positive BRIUMVI Trial Updates - Yahoo Finance
TG Therapeutics, Inc. (TGTX) Stock Analysis: Exploring a 19.52% Upside Potential in Biotechnology - DirectorsTalk Interviews
Finanzdaten der Tg Therapeutics Inc-Aktie (TGTX)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.27%
1.43%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):